Patient groups push back against Gilead’s pricey HIV prevention treatment
By Deena Beasley LOS ANGELES (Reuters) - Gilead Sciences Inc hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.
The post Patient groups push back against Gilead’s pricey HIV prevention treatment appeared first on Firstpost.
from Firstpost https://ift.tt/2yJbqAb
via IFTTT